Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFMW), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. (SBFMW) is a Montreal-based pharmaceutical innovator developing targeted therapies for oncology and antiviral treatments. This news hub provides investors and healthcare professionals with timely updates on clinical advancements, regulatory milestones, and business developments.
Access consolidated information on the company’s core initiatives including K1.1 mRNA (liver cancer), SBFM-PL4 (SARS Coronavirus), and Adva-27a (pancreatic cancer) research programs. Track updates spanning both their Generic Pharmaceuticals operations and experimental drug pipeline.
Key coverage areas include clinical trial progress, strategic partnerships, financial performance reports, and manufacturing updates. All content is sourced from official company communications to ensure reliability.
Bookmark this page for streamlined access to Sunshine Biopharma’s latest scientific breakthroughs and corporate announcements. For direct inquiries, contact CFO Camille Sebaaly at 514-814-0464.
Sunshine Biopharma has announced an agreement with the University of Arizona to advance the development of novel PLpro inhibitors. These inhibitors aim to combat SARS-CoV-2 by determining safety and efficacy in preclinical models, specifically MA10 mice. The lead compound, SBFM-PL4, is also undergoing further development at the University of Georgia. The initiative is a crucial step in enhancing treatment options against COVID-19, as highlighted by the company's CEO, Dr. Steve Slilaty.
Aegis Capital Corp. acted as the sole bookrunner for Sunshine Biopharma Inc.'s $8 million underwritten public offering, aimed at supporting the development of its COVID-19 therapeutic SBFM-PL4 and anticancer compound Adva-27a. Sunshine Biopharma is focused on creating treatments for COVID-19 and aggressive forms of cancer, including pancreatic cancer. The company is moving forward with clinical trials for Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells. This offering could potentially enhance Sunshine Biopharma's financial position as it seeks to progress its research and development initiatives.
Sunshine Biopharma announced the completion of its public offering of 1,882,353 units at $4.25 each, raising $8 million in gross proceeds. Each unit comprises one share of common stock and two warrants, both exercisable at $4.25. Aegis Capital Corp. managed the offering and was granted a 45-day option to purchase additional securities. The company is advancing SBFM-PL4, a lead compound for COVID-19 treatment, and preparing for clinical trials of Adva-27a, an anticancer drug targeting multidrug-resistant cancer cells.
Sunshine Biopharma, focused on oncology and antiviral drug development, has priced its public offering of 1,882,353 units at $4.25 each, totaling $8 million. Each unit comprises one share of common stock and two warrants, immediately separable for trading. Aegis Capital is the sole book-running manager and holds a 45-day option for an additional 15% of shares and warrants. The offering will close around February 17, 2022. Sunshine Biopharma's common stock and warrants have been approved for listing on the Nasdaq under symbols SBFM and SBFMW.
FAQ
What is the current stock price of Sunshine Biopharma (SBFMW)?
